National Ophthalmic Research Institute

Summary

National Ophthalmic Research Institute is a medical facility located in Fort Myers, Florida. This center is recognized for care of Macular Degeneration, Age-Related Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, None and other specialties. National Ophthalmic Research Institute is involved with conducting 46 clinical trials across 26 conditions. There are 4 research doctors associated with this hospital, such as A. T. Ghuman, MD, Ashish Sharma, MD, Katrina Mears, MD, and Avtar T Ghuman, MD.

Top PIs

Clinical Trials running at National Ophthalmic Research Institute

Macular Degeneration

Age-Related Macular Degeneration

Diabetic Macular Edema

Diabetic Retinopathy

Choroidal Neovascularization

Retinal Degeneration

Retinal Disease

None

Choroidal neovascularization

Wet AMD

RGX-314 Gene Therapy

for Age-Related Macular Degeneration

This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. The goal is to reduce the need for regular treatments by helping the eye produce its own protective proteins. This could make treatment easier and more effective for patients.

Recruiting

2 awards

Phase 3

2 criteria

Faricimab Schedules

for Age-Related Macular Degeneration

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Recruiting

2 awards

Phase 3

1 criteria

Pozelimab + Cemdisiran

for Macular Degeneration

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)

Recruiting

1 award

Phase 3

3 criteria